Matthew Zirwas

7PUBLICATIONS
49CO-AUTHORS
Fluid-structure interaction and aeroacousticsDisease surveillanceClinical pharmacology and therapeuticsPrecision engineeringInfant and child health
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jun 11, 2026
Roflumilast foam versus vehicle foam for seborrheic dermatitis (STRATUM clinical study): a plain language summary.

|Feb 05, 2026
Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND.

Andrew Blauvelt, H Chih-Ho Hong, Norito Katoh

|Nov 01, 2025
Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks.

Andrew F Alexis, Michael Bukhalo, Fran E Cook-Bolden

|Jul 18, 2025
The Tralokinumab Pre-Filled Pen Improved Atopic Dermatitis Signs and Symptoms and Was Well Tolerated in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 16-Week, Open-Label, Single-Arm Phase 3 Study (INJECZTRA).

Jennifer Soung, Vivian Laquer, Matthew Zirwas

|Jan 12, 2025
Tapinarof cream 1% once daily was well tolerated in adults and children with atopic dermatitis in two phase 3 randomized trials.

Linda Stein Gold, James Del Rosso, Benjamin D Ehst

|Dec 20, 2023
Rapid Improvements in Itch with Tapinarof Cream 1% Once Daily in Two Phase 3 Trials in Adults with Mild to Severe Plaque Psoriasis.

Leon Kircik, Matthew Zirwas, Shawn G Kwatra

Pageof 2

Frequent Collaborators

3 joint publications

Linda Stein Gold

2 joint publications

Andrew Blauvelt

2 joint publications

Lawrence J Green

2 joint publications

David S Rubenstein